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Many cancers are termed immuno-evasive due to expression of 
immuno-modulatory ligands. Programmed death ligand-1 (PD-L1) 
and cluster of differentiation 80/86 (CD80/86) interact with their 
receptors, (programmed death receptor-1 (PD-1) and cytotoxic T-
lymphocyte associated protein-4 (CTLA-4) respectively), on tumour 
infiltrating leukocytes, thus eliciting immunosuppression. 
Immunotherapies aimed at blocking these interactions are 
revolutionising cancer treatments, albeit in an inadequately 
described patient subset. To address the issue of patient 
stratification for immune checkpoint intervention, we have 
quantitatively imaged PD-1/PD-L1 interactions in tumour samples 
from patients, employing an assay that readily detects these 
intercellular protein-protein interactions in the ≤10nm range. These 
analyses across multiple patient cohorts demonstrate the inter-
cancer, inter-patient and intra-tumoural heterogeneity of interacting 
immune-checkpoints. We have shown that PD-1/PD-L1 interaction is 
not correlated with clinical PD-L1 expression scores in malignant 
melanoma. Crucially, amongst anti-PD-1 treated metastatic NSCLC 
patients, those with lower PD-1/PD-L1 interaction have significantly 
worsened survival. It is surmised that within tumours selecting for an 
elevated level of PD-1/PD-L1 interaction, there is a greater 
dependence on this pathway for immune evasion and hence they 
exhibit more impressive patient response to intervention. 






Statement of Significance 
Contrary to current studies, quantitation of immune-checkpoint 
interaction by direct imaging, demonstrates that, immunotherapy 
treated patients with metastatic non-small-cell lung cancer, with a 





























Disproportionate immune-system activation can result in profound 
pathologies and there are therefore regulatory mechanisms in place 
to maintain homeostasis (1). Interactions referred to as immune-
checkpoints are critical in this, avoiding immune-cell related 
collateral damage in pathogenic responses and in suppressing 
autoimmunity. Inhibitory receptors presented by immune cells, T-
cells in particular, include programmed death receptor-1 (PD-1) and 
cytotoxic T lymphocyte antigen-4 (CTLA-4) (2,3). Cancers exploit 
these physiological mechanisms to avoid immune-attack by 
expressing inhibitory receptor cognate ligands, programmed death-
ligand 1 (PD-L1) and cluster of differentiation 80/86 (CD80/86) (1). 
The CTLA-4 receptor is a homolog of the immune-activating CD28 
receptor, both of which are found on T-cells and possess CD80 and 
CD86 as ligand partners (4). CTLA-4, however, provides a higher 
affinity binding site for CD80/86 and interaction with CD80/86 
inhibits cell proliferation and interleukin-2 (IL-2) secretion by T-cells. 
The PD-1 immune checkpoint, limits later immune responses 
primarily in peripheral tissue by attenuating T-cell signalling 
downstream of the T-cell receptor (5). 
 
There are a number of approved therapeutic monoclonal antibodies 
(mAbs) designed to reinstate immune-mediated tumour destruction 
in immunogenic cancers, by inhibiting the aforementioned immune-
checkpoint interactions (6). In part through the generation of neo-
antigens, immunogenicity is strong in non-small-cell-lung-cancer 
(NSCLC), renal cell carcinomas (RCCs), melanoma, classical 
Hodgkin lymphoma, head and neck squamous cell carcinoma and 
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urothelial carcinoma, all of which show varying degrees of response 
to immune-checkpoint interventions (6-8). Notwithstanding some 
remarkable successes with immune-checkpoint inhibitors, the 
majority of patients display primary or acquired resistance to 
treatment (9). There is therefore an unmet clinical need to identify 
biomarkers that distinguish potential responders from non-
responders to ensure that non-responders are not exposed to the 
side effects of these drugs for no therapeutic benefit.  
 
The development of different PD-L1 immunohistochemistry (IHC) 
diagnostics utilising proprietary antibodies has resulted in four FDA-
approved and CE-in vitro diagnostics (IVD)-marked assays, each 
linked to a specific drug and scoring system (10). However, it has 
become clear that the expression of inhibitory ligands, namely PD-
L1, are not an accurate diagnostic marker for use in predicting 
patient prognosis and response to treatment. A recent study 
observed that NSCLC patients demonstrated an increase in 
response to the anti-PD-1 agent, pembrolizumab, in patients 
exhibiting a tumour proportion score (TPS) greater than 50% (11). 
Nevertheless, the response reached only 41% (12). Moreover, a 
different study assessed the efficacy of PD-1 or PD-L1 inhibitors in 
different neoplasia (primarily lung cancer but also renal cancer and 
malignant melanoma) in PD-L1 negative and PD-L1 positive 
cancers. Critically, benefit was seen in patients within the PD-L1 
negative group, clearly exposing the failure of PD-L1 expression to 
determine which patients should receive immune-checkpoint 




As immune-cell/tumour-cell interplay via immune-checkpoints is a 
prominent mechanism for tumour immune-evasion and survival, 
checkpoint interaction status may present a key mechanism-based 
prognostic and/or predictive biomarker, replacing conventional 
protein expression readouts for stratifying patients to immune-
checkpoint interventions. To this end we have developed and tested 
an imaging assay that provides a quantitative readout of immune-
checkpoint interaction between cells. iFRET (immune-FRET), 
employs a two-site, cell-cell amplified Förster Resonance Energy 
Transfer method, detected by Fluorescence Lifetime Imaging 
Microscopy (FRET/FLIM). Here, iFRET acts as a “chemical ruler”, 
measuring cell-cell interactions in the range of 1-10nm. Alternative 
assays have assessed the PD-1/PD-L1signalling axis in both cell 
assays and patient tissue, however these assays work at a distance 
greater than that of iFRET (Supplementary Figure 1A). Work carried 
out by Giraldo et al., 2018 uses an imaging algorithm which 
determines when PD-1+ and PD-L1+ cells are within close proximity 
(≤20 μm) of each other. Such assays investigate distances that 
reflect proximity over interaction (14). Johnson et al., 2018 also 
utilise an Automated Quantitative Analysis platform which again 
maps cells based on PD-1 and PD-L1 expression profiles. In these 
assays the colocalization of PD-1 and PD-L1 expressing cells (i.e. 
m range) is assumed to be an interaction state (15). Here, the 
intrinsic distance constraints of iFRET informs on interaction states 
as receptor and ligand pairs within 1-10nm of each other; distances 
exceeding 10nm are considered to be non-interacting.  
 
In this study we have investigated the application of iFRET in 
formalin fixed paraffin embedded (FFPE) patient tumour biopsies to 
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assess checkpoint interaction, to understand the relationship of this 
to ligand expression and to judge the predictive power of the data in 
respect of patient response to immune checkpoint interventions.  
Material and Methods  
Pathology 
ccRCC 
Biopsies from clear cell renal cell carcinoma patients, diagnosed and 
treated at the Cruces University Hospital, Bizkaia, Spain, were 
graded and staged within the study. All patients gave written 
informed consent for the potential use of their resected tumours to 
be used for research. This study was approved by the Ethical and 
Scientific Committee (CEIC-Euskadi PI2015060). The International 
Society of Urological Pathology (ISUP) 2013 tumour grading system 
(16) was used to assign each sample using routine haematoxylin 
and eosin (H&E) staining. Tumours were graded and grouped as 
low (G1/2) and high (G3/4) grade for consistency. To assess PD-L1 
expression, a multi-site tumour sampling (MSTS) method was used 
which samples more areas of a tumour with the aim of overcoming 
the problems of tissue heterogeneity (17). Samples were determined 
PD-L1 positive (>1%) or negative (<1%) using the Roche VENTANA 
PD-L1 (SP142) assay. 
Malignant Melanoma 
Cases of malignant melanoma (MM) used in this study were 
selected from all patients diagnosed with malignant melanoma 
between June 2003 and February 2017 at Nottingham University 
Hospital. The main selection criterion was tumours having a Breslow 
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thickness of >1mm. Patients gave written informed consent for their 
specimens to be stored and used for research. Patient 
clinicopathological data was obtained from Nottingham University 
Hospital PAS, WinPath and NotIS databases. Data and specimens 
were anonymised by using only their designated laboratory case 
reference. Ethical approval (ACP0000174) was gained from the 
Nottingham Health Science Biobank Access Committee. A cohort of 
176 primary MM cases was used for iFRET analysis as tissue 
microarrays (TMAs). Within the TMA’s, each patient had one tumour 
sample. Supplementary Table 2 summarises the clinical parameters 
of the 176 patients. Tumours were fully surgically excised, formalin-
fixed and paraffin embedded (FFPE) in tissue blocks. Tissue cores 
of 1mm diameter were selected by studying haematoxylin and eosin 
stained sections most recently cut from the FFPE tissue block. The 
location of cores to remove from the tissue block were selected by 
scanning the slides and using Pannoramic Viewer software 
(3DHisTech). Cores were removed from the FFPE tissue blocks 




Biopsies from 60 metastatic NSCLC tumours were obtained during 
interventional radiology procedures from Institut Bergonié 
(Supplementary Table 3). 36 patients were male and 24 female with 
a median age of 63 years (range 44-86 years). Performance status 
was defined with 50 patients given a performance status of ≤1 and 
10 patients given a status of ≥1. Performance status is a measure of 
a patients progress with a grade of 0 being defined as fully active 
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with the patient being able to carry on all pre-disease activities 
without restriction. A score of 1-3 indicates increasing severity of 
limitations to daily activities and self-care. 4 is defined as completely 
disabled and 5 defined as dead (18). The clinical outcome of 40 
patients who were treated with either nivolumab (n=37) or 
pembrolizumab (n=3) were provided and used for Kaplan-Meier 
survival analysis. Patients samples were collected between January 
2014 and December 2017. This study was approved by the IRB of 
Institut Bergonié. Excised samples were formalin fixed and paraffin 
embedded (FFPE) in tissue blocks prior to being sliced and mounted 
on microscope slides. For iFRET analysis, three consecutive tissue 
slices of each patient’s sample were provided. One slide for each 
patient was labelled with H&E and a trained pathologist (Jose 
Ignacio-Lopez) identified tumorous areas within the sample. 
Antibodies and reagents 
Monoclonal antibodies, mouse anti-PD-1 (catalogue number: 
ab52587, clone number: NAT105), rabbit anti-PD-L1 (catalogue 
number: ab205921, clone number: 28-8) and mouse anti-CTLA-4 
(catalogue number: ab19792, clone number: BNI3) were purchased 
from Abcam. Rabbit anti-CD80 (catalogue number: MBS2522916, 
clone number: MEM-233) was purchased from MyBioSource. The 
experimental antibody J1201, which blocks PD-1/PD-L1 interactions 
was obtained from Promega. Ipilimumab, which blocks CTLA-4/CD-
80 interactions was also obtained from Promega. Pierce 
endogenous peroxidase suppressor (35000), Signal Amplification kit 
(T20950) and Prolong diamond antifade mount (P36970) were 
obtained from Thermo Fisher Scientific. AffiniPure F(ab′)2 fragment 
donkey anti-mouse IgG and peroxidase-conjugated AffiniPure 
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F(ab′)2 fragment donkey anti-rabbit IgG were purchased from 
Jackson Immuno Research Laboratories. ATTO 488 NHS ester was 
purchased and was conjugated to the AffiniPure F(ab′)2 IgG as 
described by Veeriah et al. 2014 (19). Millicell® 8-well plates, 
(PEZGS0816) were purchased from Merck. 
 
Time-resolved amplified immune-Förster resonance energy 
transfer (i-FRET) detected by fluorescence lifetime imaging 
microscopy (FLIM) 
iFRET relies on a two-site labelling assay which is illustrated in 
Supplementary   1B. Briefly, two primary antibodies are used to 
detect the receptor and ligand respectively. These antibodies are 
then labelled with Fab fragments conjugated to the donor 
chromophore ATTO488 (for the receptor) and HRP for the ligand. 
Tyramide signal amplification is then use to label HRP with the 
acceptor chromophore, ALEXA594 (Supplementary Figure 2C). The 
conjugation of the chromophores to Fab fragments, which bind to 
the two primary antibodies, allows the critical FRET distance of 10 
nm or less to be maintained and provided the appropriate tool for 
measuring cell-cell interactions. It should be noted that additional 
stains, such as DAPI cannot be added to iFRET samples as they 
disrupt the ability of ATTO488 and ALEXA594 to undergo FRET. 
Using a semi-automated, high throughput mfFLIM (FASTBASE 
Solutions S.L ), a mapping file was created, which mapped each 
region of interest according to its position on the slide (Veeriah et al., 
2014 (19)) (Supplementary Methods) . Phase lifetimes, average 
intensities and lifetime images were calculated automatically and 
translated to an excel spreadsheet. A decrease of donor lifetime 
(D) in the presence of the acceptor chromophore (DA) is indicative 
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of resonance energy transfer. FRET efficiency (Ef %) values were 
calculated using the following equation, where D and DA are the 
lifetimes of the donor in the absence and presence of the acceptor, 
respectively.  




Due to the Förster radius (R0) of the chromophore pair ATTO488 
and Alexa594, the minimum distance that can exist between the 
chromophores is 5.83nm (Supplementary Figure 2B and 
Supplementary Methods). At this distance, energy transfer is 
maximal and yields a FRET efficiency of 50%.  
Immune-FRET (iFRET) assay for PD-1/PD-L1 interaction in cell 
culture 
The commercially validated Promega Blockade Bioassay, originally 
designed to measure the antibody blockade of PD-1/PD-L1 and 
CTLA-4/CD80 interaction by luminescence, was adapted for an i-
FRET protocol with the aim of verifying the technique for detecting 
intercellular interaction of these ligand/receptor pairs. Cells were 
obtained from the Promega Blockade Bioassay and were screened 
for mycoplasma prior to dispatch. These cells were thawed and 
directly used in this assay only. PD-L1 expressing CHO-K1 cells 
were seeded onto Millicell® 8-well plates and were incubated at 37 
°C with 5% CO2 for 16 hours. The experimental blocking antibody 
J1201 (anti-PD-1) was added to 4 wells at 25μg/ml final 
concentration to inhibit receptor-ligand interaction. PD-1 expressing 
Jurkat cells were subsequently seeded in all wells and the plates 
were incubated for 20 hours at 37 °C with 5% CO2. The unbound 
cells were removed and the plates washed three times for 5 minutes 
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with phosphate buffered saline (PBS) before being fixed with 4% 
paraformaldehyde (PFA) for 12 mins. The PFA was then removed 
and the plates were washed three times for 5 minutes with PBS. All 
samples were incubated with endogenous peroxidase suppressor 
for 30 minutes at room temperature before being washed with PBS. 
They were subsequently incubated with 1% (10mg/ml) Bovine 
Serum Albumin (BSA), for 1 hour at room temperature before a 
further three PBS washes.  
 
Primary antibody staining was carried out by adding mouse anti-PD-
1, (1:100 in BSA), the donor only (D) readout condition. Meanwhile 
the donor plus acceptor (D/A) readout condition was labelled with 
both anti-PD-1 (1:100) and rabbit anti-PD-L1 (1:500). The plate was 
incubated overnight at 4°C before being washed twice with PBS 
containing 0.02% Tween 20 (PBST). Secondary Fab fragments 
were added, the D wells were labelled with anti-mouse 
FabATTO488 (1:100) and the D/A wells labelled with FabATTO488 
(1:100) and anti-rabbit FabHRP (1:200). The plate was then 
incubated for 2 hours at room temperature before being washed 
twice with PBST and once with PBS. 
 
Tyramide signal amplification (TSA) was performed on the D/A wells 
for 20 minutes in the dark, via the addition of Alexa594-conjugated 
tyramide diluted in amplification buffer (1:100) in the presence of 
0.15% H2O2 (Supplementary Figure 2C) (Veeriah et al., 2014 and 
Miles et al., 2017 (19,20)) The D/A wells were washed twice with 
PBST and once with PBS to remove the tyramide. 5μl of Prolong 
Diamond anti-fade mount was added per well before being mounted 




iFRET assay for CTLA-4/CD80 interaction in cell culture 
CTLA-4 expressing Jurkat cells were first seeded onto Millicell® 8-
well plate, before the blocking antibody ipilimumab (anti-CTLA-4) 
was added to 4 wells at 100μg/ml final concentration. The CD80 
expressing Raji cells were subsequently seeded and the cells were 
incubated for 20 h at 37 °C with 5% CO2. Unbound cells were 
removed by PBS washes. The cells were fixed, underwent 
endogenous peroxidase suppression and were blocked with BSA as 
described previously in the PD-1/PD-L1 cell assay. The primary 
antibodies were added; D wells were labelled with mouse 
monoclonal anti-CTLA-4 (1:100) and the D/A wells labelled with both 
anti-CTLA-4 (1:100) and rabbit polyclonal anti-CD80 (1:100). The 
rest of the protocol was conducted as described above for the PD-
1/PD-L1 singe cell assay. 
 
iFRET assay for PD-1/PD-L1 interaction in formalin fixed 
paraffin embedded clear cell renal cell carcinoma (ccRCC) 
tissue 
Human ccRCC tissue samples were provided by Cruces University 
Hospital, Bizkaia, Spain. Consecutive cross sections of tissues were 
mounted on separate slides to allow D and D/A antibody labelling. 
Samples were from 22 patients, from which 5 consecutive tissue 
section slides were provided. Of the 5 samples, 2 were available for 
D and 2 for D/A staining, while the remaining section was analysed 
using H&E staining to determine regions of immune infiltration.  
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Immunohistochemistry with PD-L1 (SP-142, Ventana) was 
performed in Benchmark Ultra (Ventana) immunostainers following 
the specific protocol recommended by the manufacturer. 
For iFRET sample preparation, antigen retrieval was carried out 
using Envision Flex solution pH9 and a PT-Link instrument (Dako), 
where the slides were heated to 95oC for 20 minutes. Remaining 
paraffin was removed by PBS washes before containing tissue 
areas with a hydrophobic PAP pen border. 1-2 drops/slide of 
endogenous peroxidase suppressor were added and the slides were 
incubated in a humidified tray for 30 minutes at room temperature. 
The slides were then blocked with BSA and D slides labelled with 
anti-PD-1 while D/A slides were labelled with anti-PD-1 plus anti-PD-
L1, following the previously described cell assay protocol. 
iFRET assay for PD-1/PD-L1 interaction in formalin fixed 
paraffin embedded malignant melanoma TMAs 
Human malignant melanoma TMAs were provided by Nottingham 
University Hospitals, United Kingdom. Consecutive cross sections of 
tissues were mounted on separate slides to allow D and D/A 
antibody labelling. Samples from 176 patients, with two consecutive 
tissue section slides per patient were provided. Of the two samples, 
one was available for D and one for D/A staining. The primary 
antibodies used were anti-PD-1 and anti-PD-L1 following the same 
protocol as the FFPE renal cell carcinoma tissue above. 
 
 
iFRET assay for PD-1/PD-L1 interaction in formalin fixed 
paraffin embedded metastatic NSCLC 
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Human metastatic NSCLC tissue slices were provided by Institut 
Bergonié, France. Consecutive cross sections of tissues were 
mounted on separate slides to allow D and D/A antibody labelling. 
Samples from 40 patients, with two consecutive tissue section slides 
per patient were provided. Of the two samples, one was available for 
D and one for D/A staining. The primary antibodies used were anti-
PD-1 and anti-PD-L1 following the same protocol as the FFPE 




Statistical analysis and Box and Whisker plots were performed using 
Origin Pro8. Statistical differences were calculated between groups 
using the Mann-Whitney U test (values indicated on the Box and 
Whisker plots). The Mann-Whitney U test is a nonparametric test, 
thus not assuming a normal distribution of results. Box and Whisker 
plots represent the 25–75% (box) and the 1–99 (whiskers) ranges. 
Statistical differences are indicated with p values ≤0.05. Kaplan-
Meier survival analysis was performed using SPSS. SPSS was also 
used to calculate Cox-Regression for Survival Analysis to assess 
which factors (age, sex, tumour stage, interaction state) were 
impacting overall survival. For NSCLC, patients were ranked in 
order of their FRET Efficiency (interaction status) and split into the 
two groups; those with the lowest 60% of median FRET efficiencies, 
and those with the highest 40%. For melanoma, patients were split 
into the highest 20% and lowest 80% of FRET efficiencies. To 
determine these cut-off points for melanoma and NSCLC patients, 
maximally selected rank statistics were performed using the R 
statistical software (version 3.6.2) and the maxstat (version 0.7-25) 
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package which provides several p-value approximations (21,22). 
Maximally selected rank statistics can be used for estimation as well 
as evaluation of a simple cut-point mode. The results provided by 
maxstat were consistent with the choice of bottom 80% and top 20% 
and 60% and 40% respectively. The log-rank (Mantel-Cox) test was 





Development, validation and benchmarking of a novel 
amplified-FRET imaging assay for determining immune-
checkpoint interaction in ex vivo assays 
The iFRET assay used to measure immune-checkpoint interaction 
state is based on time-resolved FRET. Here, FRET acts as a 
“chemical ruler”, measuring distances of 1-10nm, which is the same 
order of magnitude as cell surface interactions. The maximum FRET 
efficiency value permitted is 50% (Supplementary Methods). Our 
definition of interaction are distances under 10nm, as opposed to 
PLA assays which detect distances of tens of nm and colocalization 
assays which range from 100nm up to 20 μm (Supplementary 
Figure 1) (14,23). 
To develop and validate iFRET for the measurement of immune-
checkpoint interactions, two antibodies (Promega) were employed; 
J1201, an experimental antibody for blocking PD-1/PD-L1 
interactions, and ipilimumab for blocking CTLA-4/CD-80 interactions. 
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These antibodies were used to verify iFRET as a technique for 
detecting the intercellular interaction of these ligand/receptor pairs. 
These antibodies and cell lines were chosen as they were 
components from a commercially available validated assay.  
Figure 1 illustrates the intercellular interaction of PD-1 and PD-L1, 
on Jurkat and CHO-K1 cells, using iFRET. Cells were not 
permeabilised and therefore the observable interaction was that of 
two membrane-bound, extracellular proteins. The FLIM images 
provided in the following figures consist of pseudocolour lifetime 
maps which represent lower lifetimes (red) and higher lifetimes 
(blue). Also provided are greyscale intensity maps which indicate 
donor (PD-1 or CTLA-4) expression and acceptor (PD-L1 or CD80) 
expression. In untreated cells, a lifetime decrease of 1.39±0.11ns to 
1.19±0.12ns was detected, resulting in a FRET efficiency of 14.38% 
(Figure 1A). FRET Efficiency is correlated to molecular distance, 
Supplementary Table 1 indicates the range of receptor-ligand 
distances obtained for the following results. In cells treated with 
25μg/ml of experimental blocking antibody J1201, the lifetime 
reduced from 1.35±0.10ns to 1.29±0.13ns, yielding a FRET 
efficiency of 4.44% (Figure 1B). iFRET signal was not observed 
when either primary staining antibody was omitted. Moreover, when 
each cell type was analysed alone, no interaction state was 
detected. The findings indicate that the decrease in donor lifetime 
reflected by the high FRET efficiency was due to the specific 
interaction of PD-1 and PD-L1, which was attenuated in the 
presence of J1201. In both cases intensity maps confirm the 
presence of the donor, PD-1 and acceptor, PD-L1. In Figure 1C, a 
Box and Whisker plot compares FRET efficiency values in the 
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absence and presence of experimental blocking antibody J1201 
(25μg/ml). Each point on the graph represents one region of interest 
which may contain between 5 and 25 cells. Mean FRET efficiencies 
+ SEM are indicated. Mann Whitney U analysis determined 
statistical differences between treated and untreated cells (**, 
p=0.004). 
Intercellular CTLA-4 and CD80 interactions, in Jurkat and Raji cells, 
were also assessed using iFRET (Figure 2). Here, in the absence of 
the blocking antibody ipilimumab, donor lifetime decrease from 
1.96±0.17ns to 1.45±0.11ns in the presence of the acceptor. This 
resulted in a FRET efficiency of 26.02% (Figure 2A). When 
ipilimumab was added at 100μg/ml, the donor lifetime decreased 
from 2.06±0.12ns to 1.98±0.09ns, resulting in a FRET efficiency of 
3.88% (Figure 2B). Intensity maps confirm the expression of CTLA-4 
(donor) and CD-80 (acceptor). Box and Whisker plot (Figure 2C) 
compares FRET efficiency values in the absence and presence of 
100μg/ml ipilimumab. Each point on the graph represents one 
region of interest which may contain between 5 and 25 cells. Mann-
Whitney U analysis determined statistical differences between 
treated and untreated cells (***, p=3.27x10-7). 
To benchmark the effectiveness of the iFRET assay in clinically 
relevant settings, we compared the assay to a Proximity Ligation 
Assay (PLA), which in principle can also visualise PD-1 and PD-L1 
within proximities of approximately 40nm. To achieve this 
comparison, iFRET and PLA analyses were run on sequential 
ccRCC tissue sections from the same tissue block. Prior to the 
investigation, samples were determined PD-L1 positive (>1%) or 
negative (<1%) using the Roche VENTANA PD-L1 (SP142) assay. 
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PLA allowed the qualitative visualisation of PD-1 and PD-L1 within 
close proximity (Supplementary Figure 3A). The PD-L1 positive 
ccRCC sample labelled with anti-PD-1, anti-PD-L1 and PLA +/- 
probes produced measurable PLA signals, albeit comparatively 
weak signals. Furthermore, PLA signals were observed across both 
experimental and control groups (normal renal tissue) possibly due 
to PLA only determining close proximity (up to 40nm) as opposed to 
direct interaction (≤10nm) limiting the specificity of the assay (24).  
The Box and Whisker plots show the interaction states in the PD-L1 
positive and PD-L1 negative groups. In the PD-L1 negative group, 
PLA fails to detect an interaction whereas iFRET detects two areas 
of significant interaction (Supplementary Figure 3B). These 
observations suggest that iFRET provides greater sensitivity and 
specificity than PLA, allowing the identification of tumour-mediated 
immune-suppression in patients otherwise considered as PD-L1 
negative.  
PD-L1 expression does not correspond to interaction status of 
PD-1 and PD-L1 in ccRCC 
Following iFRET optimisation and benchmarking, we assessed the 
interaction of PD-1 and PD-L1 in the subsequent FFPE ccRCC 
tissue sections from the above cohort of patients with as yet 
unknown outcomes. The series included samples from 22 patients 
considered as PD-L1 negative (<1%) or positive (>1%), as 
determined using the Roche VENTANA PD-L1 (SP142) assay and 
multi-site tumour sampling (MSTS). Three regions of interest per 
patient sample were analysed and the mean FRET efficiency for 
each patient calculated. Across these patients, mean FRET 
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efficiencies varied from 0.17% to 14.1%, indicating iFRET is able to 
quantitatively detect the heterogeneity of PD-1 and PD-L1 
interaction states in patients. Figure 3A shows a sample with a 
donor lifetime decrease of 1.91±0.18ns to 1.58±0.19ns this results in 
a FRET efficiency of 17.28%. Notably, PD-L1 expression, classified 
by MSTS, did not correlate with the interaction status of PD-1 and 
PD-L1 as determined by iFRET (Figure 3B). Crucially, iFRET 
detected significant interaction states in 11 out of the 12 PD-L1 
negative patients, a functional state that was not detected by 
conventional IHC methods. Conversely, one PD-L1 positive patient 
showed a minimal interaction state (Figure 3B). 
PD-1/PD-L1 interaction state is indicative of patient outcome in 
malignant melanoma 
After analysing PD-1/PD-L1 interaction in ccRCC tissue, the 
interaction status in 176 malignant melanoma patients with known 
outcomes was assessed. The cohort, which consisted of treated and 
untreated patients, was predominantly male with a split of 102M/71F 
and a mean age of 66.1 years. 25% of patients had stage I tumours, 
43.5 had stage II tumours, 9.4% had stage III tumours and 22.1% 
had stage IV tumours. Tumour infiltrating lymphocytes were absent 
in 39 patients, 101 patients had focal infiltration with 30 patients 
experiencing extensive infiltration (Supplementary Table 2). Of the 
176 patients, 148 were untreated, 14 received immunotherapies 
(nivolumab, pembrolizumab or ipilimumab) and 14 received non-
immune therapies (radiotherapy, chemotherapy or small molecule 




 Figure 4A shows the Haematoxylin and Eosin (H&E) staining of a 
primary cutaneous malignant melanoma. The left-hand panels show 
the H&E staining of patient 390, a non-ulcerated tumour sample with 
no tumour infiltrating lymphocytes, this patient had a FRET 
efficiency of 3.50%. The top panel shows a 5X magnification with 
the lack of ulceration circled, subsequent 10X magnifications show 
the lack of tumour infiltrating lymphocytes. The right-hand panels 
show patient 131, with high tumour infiltrating lymphocytes, this 
patient had a FRET efficiency 26.20%. The top panel here shows a 
5X magnification indicating the tumour infiltrating lymphocytes (black 
circled area) and tumour ulceration (blue circle). The subsequent 
middle and bottom panels show 10X magnifications of lymphocyte 
infiltration and tumour ulceration respectively. Figure 4B shows FLIM 
images of the sample of patient 390, where intensity maps illustrate 
the expression of PD-1 and PD-L1. Here, the pseudo-colour scale 
runs from 3.5ns (blue) to 0.5ns (red). Despite a high expression of 
PD-L1 in this patient’s sample, a low change in donor lifetime was 
observed; donor lifetime alone was 1.95±0.16ns and slightly 
decreased to 1.88±0.15ns in the presence of the acceptor. The 
resulting FRET efficiency is 3.50%. Conversely, Figure 4C shows 
the sample of patient 131. As observed in the sample of patient 390, 
patient 131s’ sample demonstrated a prominent level of PD-L1 
expression. However, unlike patient 390, patient 131 displayed a 
high interaction state between ligand and receptor, with the donor 
lifetime decreasing from 2.22±0.19ns to 1.64±0.15ns when in the 
presence of the acceptor, with a resulting FRET efficiency of 
26.20%.These results reinforce the hypothesis that PD-L1 




The interaction state was assessed with respect to clinical PD-L1 
expression scores for 159 of the 176 patients in this cohort (PD-L1 
scores were not available for the remaining 17 patients). Figure 5A 
shows the lack of correlation between clinical PD-L1 expression 
scores and interaction state determined by iFRET. Here, the clinical 
IHC images of patient 390 (bottom) and patient 131 (top) are shown. 
As this was performed on a TMA, each patient had one FRET 
efficiency value, with each point of the Box and Whisker plot 
representing one patients FRET efficiency. Out of the 117 patients 
who were stratified as being PD-L1 negative, 58 showed a PD-1/PD-
L1 interaction state; a functional state not detected by conventional 
IHC methods. Of the 42 patients who were in the PD-L1 positive 
group, 19 showed no interaction despite the presence of the ligand.  
 
We then correlated PD-1/PD-L1 interaction state with patient 
survival. The cohort were ranked in order of their FRET efficiency 
values and sorted into the following categories; those with the lowest 
80% of FRET efficiencies and those with the highest 20%. In Figure 
5B, Kaplan-Meier survival analysis revealed that those with the 
lowest 80% of FRET efficiencies had a significantly worse outcome 
than those with the highest 20% (Log-Rank (Mantel-Cox) p=0.05). 
Cox-Regression for Survival Analysis revealed PD-1/PD-L1 
interaction was the only significant factor impacting overall survival 
(p=0.019). We then sought to apply Kaplan-Meier analysis to 
correlate the clinical PD-L1 scores with patient outcome. In Figure 
5C, there is no significant difference in outcome between the PD-L1 
positive and PD-L1 negative patients (Log-Rank (Mantel-Cox) 
p=0.87). This illustrates that iFRET is more informative on patient 





Lower PD-1/PD-L1 interaction states correlate with worsened 
overall and progression-free survival in metastatic NSCLC. 
Next, in an outcome blinded study, we applied iFRET to samples 
from patients with metastatic NSCLC. A statistical power calculation 
indicated that, to obtain results with at least 80% significance, a 
sample number of >30 was required, hence we tested 60 FFPE 
samples, all from anti-PD-1 post-treatment patients. Of these 60 
patients, 40 had clinical follow-up and outcome and were used to 
create Kaplan-Meier survival plots. The cohort comprised of 36 
males and 24 females with an age range of 44-86 years (median 
ages 63 years) (Supplementary Table 3). Performance status was 
defined, and 50 patients had a performance status of ≤1 and 10 
patients had a status of ≥1 (see methods). 
Pathologist assessment highlighted regions of interest within each 
sample by identifying tumours and regions of immune-cell infiltration 
for each sample. In order to analyse the whole region of interest 
within a patient sample, multiple sub-regions were analysed for PD-
1/PD-L1 interaction state, resulting in a range of FRET efficiencies 
for each patient. Figure 6A shows FLIM images demonstrating that 
as in other tumour settings (see above) PD-1 and PD-L1 expression 
levels do not correlate with interaction state. The pseudo-colour 
scale (ranging from 1.0ns to 2.7ns) illustrates a donor lifetime 
decrease from 1.99±0.17ns to 1.44±0.14ns yielding a FRET 
efficiency of 27.64%. Figure 6B is a Box and Whisker plot where 
each plot represents one patient. Each plot represents all the FRET 
efficiency values obtained for each patient, with the median value 
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written above each plot. The highest median FRET efficiency value 
was 29.90% with the lowest being 0.00%. The Box and Whisker 
diagram demonstrates the ability of iFRET to quantify inter- and 
intra-patient heterogeneity of PD-1/PD-L1 interactions in metastatic 
NSCLC (Figure 6B). 
The survival data of 40 patients was subsequently analysed and 
correlated to each patient’s FRET efficiency, indicating their PD-
1/PD-L1 interaction state. Patients were then ranked in order of their 
median FRET efficiency and split into the following two groups; 
those with the highest 40% of median FRET efficiencies and those 
with the lowest 60% of median FRET efficiencies. Kaplan-Meier 
survival analysis demonstrated that for these anti-PD-1 treated 
patients, those with the lowest 60% median FRET efficiency values, 
and therefore a lower PD-1/PD-L1 interaction state had a significant 
worsened overall survival (p=0.05) (Figure 7A). When analysing PD-
L1 expression (indicated by acceptor intensity) Kaplan-Meier 
analysis failed to determine a difference between those with a high 
PD-L1 expression and those with a low PD-L1 expression (p=0.97) 
(Figure 7B). This again shows the shortcomings of using PD-L1 



















This study has demonstrated the application of iFRET to detect 
intercellular ligand-receptor interactions. The method combines a 
two-site time-resolved FRET assay and signal amplification, with a 
tissue preparation time identical to that of IHC approaches. The 
high-throughput frequency domain FRET/FLIM imaging platform 
allowed mapping and automated acquisition of data from both cell 
cultures and arrayed tissue samples, thereby creating a 
straightforward procedure for non-specialised personnel 
(Supplementary Methods). The automatic detection of regions of 





This assay measures receptor-ligand distances of 1-10nm and 
determines interaction as any distance that falls within this range. 
Currently, alternative assays have utilised PD-1 and PD-L1 
expression to determine receptor-ligand proximity. Tumeh et al., 
2014 have applied an assay which determines the presence of PD-1 
and PD-L1 in close proximity to be an interaction (25). However, the 
working distances of intensity colocalization assays are far greater 
(70nm-20μm) than that of iFRET. Moreover, when expression 
readouts have been used in the pathologies assessed here, PD-L1 
expression has not correlated with interaction state or patient 
outcome. 
 
The iFRET methodology was exemplified for assessing the 
interaction status of two immune-checkpoint pairs, PD-1/ PD-L1 and 
CTLA-4/CD80, in single-cell assays and biopsy tissue samples from 
patients with ccRCC, primary malignant melanoma and metastatic 
NSCLC. The initial validation of the method in single-cell co-culture 
assays, where manipulation of ligand-receptor interactions can be 
specifically suppressed, has provided the confidence to assess 
these complexes in patient biopsies. The additional controls with 
respect to the use of single antibodies and single secondary 
reagents add further to the validity of the assay platform and of 
course are controls than can be applied routinely to patient biopsies.  
 
Comparison of iFRET with PLA provided evidence that the latter did 
not perform as well in these settings in identifying interaction. By its 
very design, the iFRET methodology elaborated here provides both 
a measure of ligand-receptor interaction and the spatial resolution of 
this interaction. Importantly this is readily achieved in routinely fixed 
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samples from patient biopsies, offering great promise in being able 
to inform on the more detailed behaviour of these interactions and 
their distribution within pathological settings. This is well illustrated 
here with the observed heterogeneity seen not simply between 
patient biopsies but within individual biopsies reflected in the spread 
of FRET efficiencies across regions of interest for individual patients. 
This heterogeneity may reflect differential patterns of reprogramming 
of the tumour microenvironment playing out in modified immune-
suppressive ligand presentation and/or variability in the degree of 
immune-cell infiltration.  
 
A lack of correlation between the extent of PD-1/PD-L1 interaction 
state and the expression levels of these two proteins was evident in 
ccRCC, malignant melanoma and metastatic NSCLC cohorts. In 
both melanoma and NSCLC, it was shown that PD-L1 expression 
levels were unable to predict patient outcome. This questions 
current protocols which rely on IHC PD-L1 expression levels to 
predict patient outcome and thus has implications for the use of 
simple expression levels to stratify patients for treatment. Moreover, 
in ccRCC patients, high interaction states were observed in patients 
who would otherwise be labelled as PD-L1 negative. Blockade of 
interaction would be predicted to be effective in contexts where 
elevated levels of interaction occurs and is by inference responsible 
for the immune privileged state of the tumour. Hence interaction 
would a priori be a criterion for treatment. 
 
To examine the potential impact of this approach further, a unique 
cohort of patients with metastatic NSCLC were studied. The cohort 
of patients from which the FFPE samples were derived, were all 
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treated with anti-PD-1 monotherapies and had full clinical follow-up 
and outcomes. Within this cohort, iFRET has shown the potential for 
a high versus low PD-1/PD-L1 interaction state to be utilised as a 
predictive clinical biomarker post-treatment. Conceptually it is 
surmised that a high degree of PD-1/PD-L1 interaction infers tumour 
selection in patients, indicating that the patient’s tumour may be 
reliant on PD-1/PD-L1 interaction to facilitate immune evasion. It is 
precisely this group of patients that would be expected to respond to 
immune checkpoint inhibition.  
 
As these were post-treatment samples from responsive patients with 
metastatic NSCLC, it was questioned why a high level of PD-1/PD-
L1 interaction state might be observed? The pharmacodynamics of 
immune-checkpoint disruption as a measure of target interaction has 
not been monitored to date. As such it is not known whether 
blockade of checkpoint interaction needs to be either sustained or 
complete. The working hypothesis derived from this dataset is that 
interaction is likely incomplete and as such, that a threshold level of 
T lymphocyte complex disengagement is sufficient to trigger the 
observed responses to intervention. It will be informative in a 
suitable setting to monitor complex disengagement as a function of 
time following treatment. 
 
Those patients with low interaction and therefore worsened survival 
may nevertheless benefit from alternative immune therapies. These 
tumours may evade the immune system by dysregulating CTLA-
4/CD-80 or other inhibitory interactions. Furthermore, no tumour will 
discretely dysregulate one pathway, in fact, a tumour may evolve to 
evade host immune response by modulating multiple pathways 
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simultaneously, indicating a patient group who would benefit from 
dual checkpoint inhibitor therapies (26,27).  
 
iFRET can be exploited to monitor other intercellular protein 
interactions and there are ongoing developments designed to 
capture related immune modulatory interactions pertinent to cancer 
and emerging cancer treatments. This provides the potential for 
iFRET to become a useful predictive tool informing on the nature of 
the tumour immune-privileged state. However, as a principle, it is 
clear that this approach has capabilities beyond immune-tumour cell 
interactions and the broader uptake of the approach promises to be 
informative in many research (e.g. axon guidance) and clinical (e.g. 
angiopathies) settings.  
 
The exemplification of iFRET in tumour settings opens up exciting 
and powerful new opportunities to move beyond the cataloguing of 
cell phenotypes in situ and add functional attributes to our patient 
data inventory, impacting clinical decisions. This is a routine 
parameter for small molecule inhibitors targeted at driver mutations 
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Figure 1: iFRET detects and quantifies PD-1/PD-L1 interaction 
between CHO-K1 and Jurkat cells. A) FLIM images consist of 
greyscale expression maps indicating PD-1 expression (donor, 
ATTO488) and PD-L1 expression (acceptor, ALEXA594). Pseudo-
colour lifetime maps indicate the lifetime of the donor alone and 
lifetime of the donor in the presence of the acceptor. A lifetime 
decrease of 1.39±011ns to 1.19±0.12ns yields a FRET efficiency of 
14.38% in untreated cells. B) When treated with 25 μg/ml J1201 
(experimental anti-PD1 blocking antibody) the donor lifetime 
decreased from 1.35±0.10ns to 1.29±0.13ns. This gives a FRET 
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efficiency of 4.44%, indicating a significant reduction of PD-1/PD-L1 
interaction. C) Box and Whisker plot compares FRET efficiency 
values in the absence and presence of experimental blocking 
antibody J1201 (25μg/ml). Each point on the graph represents one 
region of interest which may contain between 5 and 25 cells. Mean 
FRET efficiencies + SEM are indicated. Mann Whitney U analysis 
determined statistical differences between treated and untreated 
cells (**, p=0.004).
 
Figure 2: iFRET precisely determines CTLA-4/CD-80 interaction 
between Raji and Jurkat cells. A) In untreated Raji and Jurkat 
cells, the donor lifetime decrease from 1.96±0.17ns alone to 
1.45±0.11ns in the presence of the acceptor. This gives a FRET 
efficiency of 26.02%. B) When treated with 100μg ipilimumab, donor 
lifetime decreased from 2.06±0.12ns to 1.98±0.09ns. This results in 
a FRET efficiency of 3.88%. C) Box and Whisker plot compares 
FRET efficiency values in the absence and presence of 100μg/ml 
ipilimumab. Each point on the graph represents one region of 
interest which may contain between 5 and 25 cells. Mann-Whitney U 
analysis determined statistical differences between treated and 
untreated cells (***, p=3.27x10-7). 
 
Figure 3: iFRET detects heterogeneity of PD-1 and PD-L1 
interaction in FFPE ccRCC. A) Intensity images and lifetime maps 
(pseudo-colour scale) of FFPE human ccRCC patient sample 16-
15203. A decrease in donor lifetime from1.91±0.18ns alone, to 
1.58±0.19ns in the presence of the acceptor gives a FRET efficiency 
of 17.28%. B) Box and Whisker plots shown the interaction state of 
each patient in either the PD-L1 negative or PD-1 positive group. 
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Here, iFRET identifies that 11 of the 12 PD-L1 negative patients had 
a significant interaction state. Conversely, 1 patient in the PD-L1 
positive group exhibited no interaction state.  
 
Figure 4: PD-L1 expression does not correlate with PD-1/PD-L1 
interaction state in malignant melanoma. A) The left-hand panels 
show the H&E staining of the sample of patient 390 with a FRET 
efficiency of 3.50%. The top panel shows a scanning view of the 
non-ulcerated (blue circle) tumour at 5X with the subsequent images 
showing high power (10X) images of the tumour, highlighting a lack 
of tumour infiltrating leukocytes. Right hand panels show the H&E 
staining of patient 131 with a FRET efficiency of 26.20%. The top 
panel shows a scanning view of the tumour with the tumour 
infiltrating leukocytes shown (black marked area) and tumour 
ulceration (blue circle). The middle and bottom panels show tumour 
leukocyte infiltration and tumour ulceration respectively at a 
magnification of 10X. B) Fluorescence lifetime imaging microscopy 
(FLIM) images show a melanoma with a low PD-1/PD-L1 interaction 
state. Expression images, based on PD-1 or PD-L1 intensity, show 
the presence of the receptor and ligand, however, the lifetime map 
shows no change in pseudo-colour, indicating a lifetime change of 
1.95±0.16ns to 1.88±0.15ns and thus no interaction state C) FLIM 
images show a melanoma sample with a high PD-1/PD-L1 
interaction state. Again, the expression maps show the presence of 
PD-1 and PD-L1 as in panel B, however the change in pseudo-
colour represents a change in lifetime of 2.22±0.19ns to 1.64±0.15, 
indicating a high interaction state. 
 
Figure 5: PD-1/PD-L1 interaction state predicts patient outcome 
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in malignant melanoma where PD-L1 expression fails to do so. 
A) PD-L1 was labelled and patients clinical PD-L1 expressions were 
determined as PD-L1 negative or PD-L1 positive. PD-L1 expression 
status was correlated with interaction state. Within the patients’ 
assessed as PD-L1 negative, iFRET determined 58 patients which 
show an interaction state, with 59 patients in the PD-L1 negative 
group showing no interaction state. Conversely, in those patients 
clinically stratified as PD-L1 positive, iFRET determines that 19 out 
of 42 patients show no interaction state. The IHC PD-L1 images of 
patients 390 and 131, with FRET efficiencies of 3.50% and 26.2% 
respectively are shown. B) Kaplan-Meier survival analyses 
comparing patients with the highest 20% of FRET efficiencies and 
those with the lowest 80% (n=176). Those with a lower PD-1/PD-L1 
interaction state (lower FRET efficiency) had an improved overall 
survival compared to those with a higher interaction state (Log Rank 
(Mantel-Cox) p=0.05), underpinning the ability of iFRET to predict 
patient outcome. C) Clinical PD-L1 scores defined patients as being 
PD-L1 positive or PD-L1 negative. Kaplan-Meier analysis detected 
no significant difference in patient outcome when correlated with 
PD-L1 expression (Log Rank (Mantel-Cox) p=0.87) exhibiting that 
PD-L1 expression levels fail to predict patient outcome 
 
Figure 6: iFRET quantifies PD-1/PD-L1 interaction state in 
metastatic NSCLC alongside inter- and intra-patient 
heterogeneity. A) FLIM images show intensity and lifetime maps of 
a FFPE metastatic NSCLC sample. Intensity images show PD-1 and 
PD-L1 expressions respectively. The pseudo-colour scale illustrates 
a donor lifetime decrease from 1.99±0.17ns to 1.44±0.14ns yielding 
a FRET efficiency of 27.64%. B) Box and Whisker plots quantify the 
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interaction states observed with each plot representing the 
interaction states detected within each patient sample. Values above 
each plot represent the median FRET efficiency value for each 
patient sample. The highest median FRET efficiency value observed 
was 29.90% and the lowest 0.00%. iFRET not only quantifies inter-
patient heterogeneity but also intra-patient heterogeneity.  
 
Figure 7: Lower PD-1/PD-L1 interaction correlates to a 
significantly worsened patient survival in metastatic NSCLC. A) 
Anti-PD-1 post-treatment patients were ranked by their mean FRET 
efficiency value and grouped into the following: the lowest 60% of 
median FRET efficiencies and the highest 40% of median FRET 
efficiencies. Those with the lowest 60% of median FRET efficiencies 
had a significantly (p=0.05) worsened overall survival. B) Patients 
were ranked by their PD-L1 expression (acceptor intensity) and split 
into the lowest 60% of median acceptor intensities and the highest 
40%. Kaplan-Meier survival analysis was unable to detect a 
difference between the two groups (Log Rank (Mantel-Cox) p=0.97). 
 
 







